Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (8297)	1/15/1999 12:17:00 AM
From: Phil Placier	Respond to of 17367

To: LarryS who wrote (8297)	1/15/1999 12:53:00 AM
From: aknahow	Respond to of 17367

I hope he does mention XOMA. I think logic helps one understand that the end of the trials must be close. How close, I don't know, but I have begun to see how the short delay in termination of the trial might actually be due to what we have often thought, lower death rates due to faster diagnosis and treatment. Lower death rates due to Neuprex also being effective might be a factor in some perverse way in having the trial run on a bit. Of course, that is, if Neuprex is really effective. At any rate I think XOMA is the most accurate source of information on just when the DSMB meets or the trials end.

To: LarryS who wrote (8297)	1/15/1999 10:23:00 AM
From: aknahow	Respond to of 17367

Larry, see you on Yahoo so this partial quote from slgonzalez is probably not new to you. "With total mortality being critical by: slgonzalez 4727 of 4727 ...to the design and power of the investigation, the total mortality number must be met for the proper focus to statistically capture the Neuprex story in meningococcemia. It is optimistic, IMO, that that number forcasted by the stats folks has not been met by the total number of patients studied thus far. Seems likely that there is something more than rapid diagnosis and optimal treatment going on, i.e. maybe a (very) high survival rate in the treatment arm? As if life or death is not enough, there are other endpoints besides and beyond this whole discussion." Me again, not Gonzalea! I am absolutly delighted with this as I share the thoughts of Gonzalez. She has certainly explained the situation much more clearly than I could have done.